Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on ...

In research published in Developmental Medicine & Child Neurology, investigators have developed a brief, reliable, and valid ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

There are celebrations galore as Jack Johnson – the inspiration for Wigan-based charity Joining Jack – marks his 18th ...

The inaugural Steps For Hope 5K is set to take place in Brick, New Jersey, organized by LeTip of Brick in partnership with ...

In research published in Developmental Medicine & Child Neurology , investigators developed a brief, reliable, and valid screening tool to help ...

Solid Biosciences (SLDB) stock rises as a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy reaches ...

In research published in Developmental Medicine & Child Neurology , investigators developed a brief, reliable, and valid screening tool to help identify individuals with Duchenne muscular dystrophy (a ...

US FDA grants Orphan Drug Designation to Atossa Therapeutics’ (Z)-endoxifen to treat Duchenne muscular dystrophy: Seattle Monday, January 19, 2026, 17:00 Hrs [IST] Atossa Therap ...

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE ...

“They're not looking at the bigger picture; they're just looking at dollar signs. I don't want to be labeled as a dollar sign ...

Shares of  Regenxbio rose Monday in premarket trading after the company said its treatment for Duchenne muscular dystrophy delivered positive trial results, strengthening the case for a speedier ...